4 completed, 1 terminated. 4 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 3, Terminated 1 |
| Phase 1 | 1 | Completed 1 |
Follow MK-6096: new trials by email Literature Review of MK-6096 trials Research Report on MK-6096
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Efficacy of MK-6096 as Adjunctive Therapy in Participants With Major Depressive Disorder And Partial Response to Antidepressant Monotherapy (MK-6096-022) Filorexant, Placebo - Major Depressive Disorder, Recurrent | Phase 2 | Terminated | Merck Sharp & Dohme LLC | 129 | 2012-05-18 | 2018-11-07 |
| Study to Evaluate MK-6096 in the Treatment of Painful Diabetic Neuropathy (PDN) in Adults (MK-6096-021) MK-6096, Placebo - Diabetic Neuropathy, Painful | Phase 2 | Completed | Merck Sharp & Dohme LLC | 170 | 2012-03-26 | 2018-11-07 |
| A Study of the Safety and Efficacy of MK-6096 for Migraine Prophylaxis in Participants With Episodic Migraine (MK-6096-020) MK-6096, Placebo - Migraine, Headache | Phase 2 | Completed | Merck Sharp & Dohme LLC | 237 | 2012-02-06 | 2018-11-07 |
| Polysomnography Study of MK-6096 in Participants With Primary Insomnia (MK-6096-011) MK-6096, Dose-matched Placebo to MK-6096 - Primary Insomnia | Phase 2 | Completed | Merck Sharp & Dohme LLC | 326 | 2009-11-30 | 2018-11-06 |
| A Study to Evaluate the Effects of Single Doses of MK-1064 and MK-6096 on Polysomnography (PSG) (MK-1064-003) MK-1064, MK-6096, Placebo - Polysomnography | Phase 1 | Completed | Merck Sharp & Dohme LLC | 20 | 2009-11-06 | 2018-10-23 |
Depressive Disorder, Major (1) · Diabetic Neuropathies (1) · Headache (1) · Migraine Disorders (1) · Recurrence (1) · Sleep Initiation and Maintenance Disorders (1)